|
|
 |
Mechanism of Action
STALEVO provides more consistent and reliable delivery of levodopa
STALEVO blocks both major enzymes that break down levodopa
 |
35% to 40% greater levodopa plasma AUC with every administration
|
|
85% greater half-life than traditional levodopa (2.4 h vs 1.3 h)
|
The patients on STALEVO demonstrated greater, more sustained levodopa plasma levels
STALEVO significantly increases "on" and decreases "off" time
|
Mean daily "on" time increased 1.4 hours more in the entacapone
group than in the placebo group (measured by home diaries over an 18-hour period) as demonstrated
in NOMECOMT, a randomized, double-blind, placebo-controlled, 24-week trial
|
|
Mean daily "off" time decreased by 1.3 hours more in the entacapone
group than in the placebo group (measured by home diaries over an 18-hour period) as demonstrated
in NOMECOMT
|
|
Similar results were seen with levodopa/DDCI* + entacapone in 2
additional, randomized, double-blind trials (n=506)
|
Please see Important Safety Information.
|
|
